EU marketing authorization for ViiV Healthcare HIV drug Triumeq

The European Commission has granted marketing authorization for ViiV Healthcare’s Triumeq(dolutegravir 50mg/abacavir 600mg/lamivudine 300mg) tablets for the treatment of HIV in adults and adolescents aged 12 years and older.

Triumeq is ViiV Healthcare’s first once-daily single-pill dolutegravir-based regimen that combines the integrase strand transfer inhibitor (INSTI) dolutegravir, with the nucleoside reverse transcriptase inhibitors (NRTIs) abacavir and lamivudine. Just last month, the drug was approved by the US Food and Drug Administration (The Pharma Letter August 23).

Viiv is a joint venture set up in 2009 that has UK pharma major GlaxoSmithKline (LSE: GSK) as the major partner (76.5%) with US drugs giant Pfizer (NYSE: PFE), with both transferring their AIDS assets into the new company. Japan’s Shionogi (TYO: 4507) joined in 2013 as a minority stakeholder (10%).